Looking for Tocilizumab found 14 matches
|
| Open monograph to display formulary status |
BNF Category |
| |
Tocilizumab
(RoActemra®)
|
Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
|
| |
 Remdesivir
(Veklury®)
|
Infections - COVID-19 therapeutics - 05.03.06
|
| |
Links Link to Drug Section  Link to document |
|
MHRA Drug Safety Update (July 2019): Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation (10.01.03)
|
|
NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA518: Tocilizumab for treating giant cell arteritis (10.01.03)
|
|
NICE TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (05.03.06)
|
|
NICE TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (05.03.06)
|
|
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (05.03.06)
|
|
North of Tyne, Gateshead and North Cumbria - Tocilizumab monitoring Shared Care Guideline 2023 (10.01.03)
|
|
|
